Study finds 'dramatic' benefit from Pfizer's breast cancer hopeful

Strong Phase II data for Pfizer's ($PFE) dual-kinase blocker for breast cancer has analysts anticipating a "mega-blockbuster" as the drugmaker aims to launch Phase III next year. Report

Read more on